Abstract:Background: N6-methyladenosine (m6A) modification is a part of epigenetic research that has gained increasing attention in recent years. m6A modification is widely involved in many biological behaviors of intracellular RNA by regulating mRNA, thus affecting disease progression and tumor occurrence. However, the effects of m6A modification on immune cell infiltration of the tumor microenvironment (TME) are uncertain in stomach adenocarcinoma (STAD). Methods: The Cancer Genome Map (TCGA) database was used to download transcriptome data, clinicopathological data, and survival data for m6A-regulated genes in 433 STAD tissues that meet the requirements of this study. GSE84437 data were obtained from the Gene Expression Omnibus (GEO) database. The correlation between 23 m6A regulated genes was analyzed using R software. Sample clustering analysis was carried out on the genes of the m6A regulatory factor, and survival analysis and differentiation comparison were made for patients in clustering grouping. Then, the Gene Set Enrichment Analysis (GSEA), the single-sample GSEA (ssGSEA), and other methods were conducted to assess the correlation among m6A modification patterns, TME cell infiltration characteristics, and immune infiltration markers. The m6A modification pattern of individual tumors was quantitatively evaluated using the m6A score scheme of the principal component analysis (PCA). Results: From the TCGA database, 94/433 (21.71%) samples were somatic cell mutations, and ZC3H13 mutations are the most common. Based on the consensus, matrix k-3 is an optimal clustering stability value to identify three different clusters. Three types of m6A methylation modification patterns were significantly different in immune infiltration. Thus, 1028 differentially expressed genes (DEGs) were identified. The survival analysis of the m6A score found that patients in the high m6A score group had a better prognosis than those in the low m6A score group. Further analysis of the survival curve combining tumor mutation burden (TMB) and m6A scores revealed that patients had a significantly lower prognosis in the low tumor mutant group and the low m6A score group ( p = 0.003). The results showed that PD-L1 was significantly higher in the high m6A score group than in the low score group ( p < 2.22e-16). The high-frequency microsatellite instability (MSI-H) subtype score was significantly different from the other two groups. Conclusions: This study systematically evaluated the modification patterns of 23 m6A regulatory factors in STAD. The m6A modification pattern may be a critical factor leading to inhibitory changes and heterogeneity in TME. This elucidated the TME infiltration characteristics in patients with STAD through the evaluation of the m6A modification pattern.

N6-Methyladenosine Regulator-Mediated Methylation Modification Patterns with Distinct Prognosis, Oxidative Stress, and Tumor Microenvironment in Renal Cell Carcinoma

Establishment of a Risk Signature Based on M6a RNA Methylation Regulators That Predicts Poor Prognosis in Renal Cell Carcinoma

m6A Methylation Patterns and Tumor Microenvironment Infiltration Characterization in Clear-Cell Renal Cell Carcinoma

N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma

A Signature Based on M6a Pattern and Tumor Microenvironment Infiltration in Clear Cell Renal Cell Carcinoma.

Application of m6A and TME in Predicting the Prognosis and Treatment of Clear Cell Renal Cell Carcinoma

m<SUP>6</SUP>A Regulator-Based Methylation Modification Patterns Characterized by Distinct Tumor Microenvironment Immune Profiles in Rectal Cancer

N6-methyladenosine Related Gene Expression Signatures for Predicting the Overall Survival and Immune Responses of Patients with Colorectal Cancer

m6A-mRNA Methylation Regulates Gene Expression and Programmable m6A Modification of Cellular RNAs With CRISPR-Cas13b in Renal Cell Carcinoma

RNA Modification of N6-Methyladenosine Predicts Immune Phenotypes and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma

Transcriptome-wide Landscape of RNA Modification N6-Methyladenosine in Chromophobe Renal Cell Carcinoma

Comprehensive analysis of m6A methylome and transcriptome by Nanopore sequencing in clear cell renal carcinoma

N6-methyladenosine RNA Methylation Regulators Participate in Malignant Progression and Have Prognostic Value in Clear Cell Renal Cell Carcinoma

Comprehensive Analyses of Molecular Features, Prognostic Values, and Regulatory Functionalities of M6a-Modified Long Non-Coding RNAs in Lung Adenocarcinoma.

M6a Regulator-Mediated Methylation Modification Model Predicts Prognosis, Tumor Microenvironment Characterizations and Response to Immunotherapies of Clear Cell Renal Cell Carcinoma

m<SUP>6</SUP>A-mRNA Methylation Regulates Gene Expression and Programmable m<SUP>6</SUP>A Modification of Cellular RNAs With CRISPR-Cas13b in Renal Cell Carcinoma

A Novel M6a Gene Signature Associated with Regulatory Immune Function for Prognosis Prediction in Clear-Cell Renal Cell Carcinoma

Effect of M6a RNA Methylation Regulators on Malignant Progression and Prognosis in Renal Clear Cell Carcinoma.

Gene Signatures And Prognostic Values Of M6a Regulators In Clear Cell Renal Cell Carcinoma - A Retrospective Study Using Tcga Dataoase

Comprehensive Analysis Revealed the Potential Implications of m6A Regulators in Lung Adenocarcinoma

Pan-Cancer Prognostic, Immunity, Stemness, and Anticancer Drug Sensitivity Characterization of N6-Methyladenosine RNA Modification Regulators in Human Cancers